Ergocornine and 2-Br-alpha-ergocryptine. Evidence for prolonged dopamine receptor stimulation.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects*; D001966:Bromine / Q000008:administration & dosage / Q000494:pharmacology; D002540:Cerebral Cortex / Q000187:drug effects; D002628:Chemoreceptor Cells / Q000187:drug effects*; D003342:Corpus Striatum / Q000187:drug effects; D003864:Depression, Chemical; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004876:Ergot Alkaloids / Q000008:administration & dosage / Q000494:pharmacology*; D006614:Hindlimb / Q000187:drug effects; D007031:Hypothalamus / Q000187:drug effects; D008032:Limbic System / Q000187:drug effects; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism*; D009833:Olfactory Pathways / Q000187:drug effects; D010868:Pimozide / Q000494:pharmacology; D051381:Rats; D012018:Reflex / Q000187:drug effects; D013268:Stimulation, Chemical
D004876:Ergot Alkaloids; D008781:Methyltyrosines; D010868:Pimozide; D001058:Apomorphine; D001966:Bromine; D004298:Dopamine; D009638:Norepinephrine